Importantly, trabectedin overcomes microenvironment-induced resistance, impairs MM-macrophages-mediated neo-angiogenesis, and induces NKG2D ligands upregulation enhancing NK-mediated killing. Here, KLRK1 is linked to Miyoshi myopathy.